|Videos|May 5, 2022
First-line Treatment Strategies for BRAF-Mutant Metastatic Melanoma: Ipilimumab & Nivolumab
Author(s)Michael Atkins, MD, Evan Lipson, MD
Dr Michael Atkins and Dr Evan Lipson review data from the DREAMseq trial, which evaluated nivolumab plus ipilimumab, in treatment-naïve patients with BRAFV600-mutated melanoma.
Advertisement
Episodes in this series
Advertisement
Related to this article
Phase 1 data support continued investigation of roginolisib in advanced cancers, including metastatic uveal melanoma.
The NCCN update adds locally advanced CSCC to the category 2A listing that cosibelimab received for metastatic disease in 2025.
The CHMP opinion supports 700 mg every 6 weeks after 12 weeks of 350 mg every 3 weeks; a European Commission decision is expected in the coming months.
New severe treatment-related adverse effects after discharge from lifileucel therapy were uncommon and emerged across several months.
Advertisement
Advertisement
Trending on OncLive
1
Tolerability Remains a TROP2-Directed ADC Hurdle in EGFR-Mutated NSCLC
2
Pembrolizumab Plus Enfortumab Vedotin Earns EC Approval in Resectable MIBC
3
Experts Tackle Key Questions on CDK4/6 Inhibition Across HR+ Breast Cancer Settings
4
Dr Oberstein on the Rationale for Evaluating the PD-1/IL-15 Fusion Protein SAR445877 in MSS CRC
5